Finn Gustafsson

Has grant

Professor

University of Copenhagen

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Finn Gustafsson is a Professor at the University of Copenhagen, Denmark. His research areas include heart failure, aortic stenosis, and advancements in treatment protocols for cardiovascular conditions, as evidenced by his recent publications. He has contributed significantly to clinical consensus statements and scientific guidelines in the field of heart failure management.

Recent Grants

Grant: Close

Distinguished clinical investigator

Open Date:

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

Omid Rezahosseini

University of Copenhagen

DENMARK

View details

Andreas Kjaer

DENMARK

View details

Abbas Bitar

University of Michigan

UNITED STATES

View details

Kieran Docherty

University of Glasgow

UNITED KINGDOM

View details

Marit Eika Jørgensen

University of Southern Denmark

DENMARK

View details

Steffen Heegaard

DENMARK

View details

Anna Cantone

University of Ferrara

ITALY

View details

Antoni Bayes-Genis

Full Professor (Catedrático)

University of Barcelona

SPAIN

View details

Kevin Veen

Erasmus University Rotterdam

NETHERLANDS

View details

Thomas Scheike

Københavns Universitet

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Finn Gustafsson

Research Interests

Contact this professor

About

Recent Grants

Articles (20)

Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.

A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial.

Current Practices and Perspectives on the Use of Intravenous Vasodilators in Acute Heart Failure: An International Survey.

Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC.

Comment on Aspirin Avoidance in Patients With LVADs-Reply.

Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy

Risk prediction model for waitlist mortality in patients with left ventricular assist devices.

Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration.

Donor heart allocation systems in Europe. A scientific statement of the Heart Failure Association of the ESC.

Glaucoma is probably not useful as a red flag for amyloidosis.

Prevalence and clinical features of heart failure in Greenland.

Case of High Output Heart Failure Caused by Renal Clear Cell Carcinoma

Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC.

Interatrial shunt devices for heart failure

Importance of heart failure duration for development of pulmonary hypertension in advanced heart failure.

Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3.

Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial.

Prediction of herpes virus infections after solid organ transplantation: a prospective study of immune function.

The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.

Collaborators (10)

Omid Rezahosseini

Andreas Kjaer

Abbas Bitar

Kieran Docherty

Marit Eika Jørgensen

Steffen Heegaard

Anna Cantone

Antoni Bayes-Genis

Kevin Veen

Thomas Scheike

Make your next move.